Comparison

Recombinant Human IgSF11 (N-Terminal) Protein

Item no. 230-30108-200
Manufacturer Raybiotech
Amount 200 ug
Quantity options 10 ug 200 ug 50 ug
Category
Type Proteins Recombinant
Format Lyophilized
Applications WB, IP, ELISA, Dot
Specific against Human (Homo sapiens)
Host HEK293 cells
Conjugate/Tag HIS
Purity >95%
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Shipping Condition Room temperature
Available
Manufacturer - Applications
Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.
Manufacturer - Category
Proteins|Recombinant Proteins|Human Proteins
Manufacturer - Conjugate / Tag
N-terminal histidine tag
Shipping Temperature
Ambient temperature
Storage Conditions
-20°C
Molecular Weight
Recombinant human IgSF11 protein has a calculated molecular mass of 24 kDa. Due to the abundant glycosylation, it migrates as approximately 30-35 kDa protein band in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions.
Description
Recombinant human immunoglobulin superfamily, member 11, derived from transfected human HEK293 cells.
Purity determined by
SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Gene Symbols
IGSF11
UNSPSC Code
12352202
Formulation
Lyophilized from a 0.2 µm filtered solution in PBS
Expressed Region
Ala20-Gly244
Protein Name & Synonyms
IgSF11, N-terminal, Immunoglobulin Superfamily, Member 11, Brain And Testis-Specific Immunoglobulin Superfamily Protein, V-Set And Immunoglobulin Domain-Containing Protein 3, Cancer/Testis Antigen 119, BT-IgSF, CXADRL1, VSIG3, V-Set And Immunoglobulin Domain Containing 3, CXADR Like 1, IgSF13, BTIGSF, IgSF11, CT119
Format
Lyophilized powder
Purification
His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Concentration
Determined by Pierce BCA protein assay kit
Reconstitution
Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1.0 mg/mL with sterile deionized water.
SDS-PAGE Image
Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with Protein Deglycosylation Kit under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated. Lane 1: Protein standard ladder (kDa) Lane 2: Untreated protein under reducing conditions Lane 3: Treated protein with deglycosylation enzymes under native conditions Lane 4: Treated protein with deglycosylation enzymes under reducing conditions.Lane 5: Deglycosylation mixture only without target proteins.
Custom Labeling Request
We can custom label this protein with biotin or fluorescent dyes (choose from violet, blue, green or red). Request now.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 200 ug
Available: In stock
available

Delivery expected until 10/16/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close